1. Home
  2. BA vs AZN Comparison

BA vs AZN Comparison

Compare BA & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boeing Company (The)

BA

Boeing Company (The)

HOLD

Current Price

$216.75

Market Cap

182.2B

Sector

Industrials

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$181.02

Market Cap

316.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BA
AZN
Founded
1916
1992
Country
United States
United Kingdom
Employees
N/A
96100
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.2B
316.4B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
BA
AZN
Price
$216.75
$181.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
1
Target Price
$269.75
N/A
AVG Volume (30 Days)
6.1M
1.9M
Earning Date
04-22-2026
04-29-2026
Dividend Yield
N/A
1.73%
EPS Growth
113.51
N/A
EPS
N/A
N/A
Revenue
$89,463,000,000.00
N/A
Revenue This Year
$12.16
$10.34
Revenue Next Year
$14.78
$6.43
P/E Ratio
N/A
$31.91
Revenue Growth
34.50
N/A
52 Week Low
$176.77
$68.62
52 Week High
$254.35
$212.71

Technical Indicators

Market Signals
Indicator
BA
AZN
Relative Strength Index (RSI) 45.69 48.19
Support Level $211.89 $174.60
Resistance Level $228.58 $191.50
Average True Range (ATR) 6.35 3.02
MACD 0.27 -0.03
Stochastic Oscillator 37.49 54.11

Price Performance

Historical Comparison
BA
AZN

About BA Boeing Company (The)

Boeing is a major aerospace and defense firm operating in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: